Incidence and risk of advanced age-related macular degeneration in eyes with drusenoid pigment epithelial detachment

Abstract

Purpose To investigate the incidence and risk of advanced age-related macular degeneration (AMD), including geographic atrophy (GA) and macular neovascularization (MNV), in eyes with drusenoid pigment epithelial detachment (PED). Methods Eighty-five eyes with drusenoid PED from 85 patients (77.2 ± 7.0 years, male/female:44/41) were included in this study. Patients were followed up every 1–3 months via spectral-domain optical coherence tomography (SD-OCT) and color fundus photography. If exudation was observed on SD-OCT, fluorescein and indocyanine green angiography were performed to confirm the MNV subtype accordingly. The maximum follow-up period was 60 months. Results During the study period, GA developed in 8 eyes while MNV also developed in 8 eyes. The Kaplan-Meier estimator revealed that the cumulative incidence for 60 months was 17.9% and 12.2% for GA and MNV, respectively. In eyes developing MNV, retinal angiomatous proliferation (type 3 neovascularization) was the most common. Cox regression analysis revealed that baseline PED width was the only factor associated with advanced AMD. (p = 0.006, Cox regression analysis). Conclusions The five-year cumulative incidence of advanced AMD, including GA and MNV, was approximately 30% in eyes with drusenoid PED among the Japanese elderly. A larger baseline PED width was the only risk factor for advanced AMD.

Faricimab in neovascular AMD: first report of real-world outcomes in an independent retina clinic

“…Drusenoid PED pathogenesis and its implication in nAMD is still unknown but it is though that they are associated with an increased risk of advanced AMD with atrophy or brosis development (34). Thus, achieving a attening or reduction in a PED early in disease might be of bene t. Javaheri et al demonstrated that one-third of 586 eyes had a attened PED after an initial ranibizumab injection (35).…”